From clonal hematopoiesis to myeloid leukemia and what happens in between: Will improved understanding lead to new therapeutic and preventive opportunities?
- PMID: 31400824
- DOI: 10.1016/j.blre.2019.100587
From clonal hematopoiesis to myeloid leukemia and what happens in between: Will improved understanding lead to new therapeutic and preventive opportunities?
Abstract
Clonal hematopoiesis (CH) as defined by the presence of somatic mutations in genes associated with myeloid neoplasms (MN) is common in healthy elderly individuals and does not necessarily constitute a premalignant state. Several acronyms (idiopathic cytopenia of undetermined significance [ICUS], clonal cytopenia of undetermined significance [CCUS], CH of indeterminate potential [CHIP]) related to CH have been coined to describe patients who do not meet the diagnostic criteria for other hematologic disorders. CHIP carries an annual progression rate to MN of 0.5-1.0% as well as an increased risk of cardiovascular mortality and development of therapy-related MN in patients with solid tumors. Further studies on the natural history of ICUS, CCUS, and CHIP and to assess the risk for progression to MN are needed. Herein, we review the current understanding and clinical significance of these conditions to guide physicians in the interpretation of genetic testing results in various clinical settings.
Keywords: CCUS; CHIP; Clonal hematopoiesis; Genetic testing; ICUS; Myeloid neoplasm.
Copyright © 2019. Published by Elsevier Ltd.
Similar articles
-
Diagnostic Challenge and Clinical Dilemma: The Long Reach of Clonal Hematopoiesis.Clin Chem. 2021 Aug 5;67(8):1062-1070. doi: 10.1093/clinchem/hvab105. Clin Chem. 2021. PMID: 34263288 Review.
-
Current Aspects of Clonal Hematopoiesis: Implications for Clinical Diagnosis.Ann Lab Med. 2019 Nov;39(6):509-514. doi: 10.3343/alm.2019.39.6.509. Ann Lab Med. 2019. PMID: 31240877 Free PMC article. Review.
-
[Clonal hematopoiesis of undetermined potential (CHIP) and clonal cytopenia of unknown significance (CCUS) - Consequences for the clinic].Dtsch Med Wochenschr. 2023 Apr;148(8):441-450. doi: 10.1055/a-1873-4250. Epub 2023 Mar 29. Dtsch Med Wochenschr. 2023. PMID: 36990116 Review. German.
-
ICUS/CCUS/CHIP: basics & beyond.Expert Rev Hematol. 2017 Oct;10(10):915-920. doi: 10.1080/17474086.2017.1371588. Epub 2017 Sep 1. Expert Rev Hematol. 2017. PMID: 28832236 Review.
-
Review of clonal hematopoiesis, subtypes and its role in neoplasia and different morbidities.Leuk Res. 2023 Jul;130:107307. doi: 10.1016/j.leukres.2023.107307. Epub 2023 May 5. Leuk Res. 2023. PMID: 37186988 Review.
Cited by
-
High Expression of ENO1 and Low Levels of Circulating Anti-ENO1 Autoantibodies in Patients with Myelodysplastic Neoplasms and Acute Myeloid Leukaemia.Cancers (Basel). 2024 Feb 22;16(5):884. doi: 10.3390/cancers16050884. Cancers (Basel). 2024. PMID: 38473245 Free PMC article.
-
The molecular profile in patients with polycythemia vera and essential thrombocythemia is dynamic and correlates with disease's phenotype.Front Oncol. 2023 Aug 21;13:1224590. doi: 10.3389/fonc.2023.1224590. eCollection 2023. Front Oncol. 2023. PMID: 37671053 Free PMC article.
-
Clonal Hematopoiesis of Indeterminate Potential: Current Understanding and Future Directions.Curr Oncol Rep. 2023 Jun;25(6):539-547. doi: 10.1007/s11912-023-01382-9. Epub 2023 Mar 16. Curr Oncol Rep. 2023. PMID: 36928826 Review.
-
Predictors of vascular disease in myelodysplastic syndromes.EJHaem. 2020 Sep 28;1(2):467-472. doi: 10.1002/jha2.101. eCollection 2020 Nov. EJHaem. 2020. PMID: 35845007 Free PMC article.
-
Mutant PPM1D- and TP53-Driven Hematopoiesis Populates the Hematopoietic Compartment in Response to Peptide Receptor Radionuclide Therapy.JCO Precis Oncol. 2022 Jan;6:e2100309. doi: 10.1200/PO.21.00309. JCO Precis Oncol. 2022. PMID: 35025619 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
